Abstract :

Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing the pharmaceutical sector at every stage—drug discovery, development, regulatory affairs, quality control, and post-marketing surveillance. These technologies improve data processing, accuracy, and timelines by using complex algorithms and large volumes of healthcare data. AI helps in drug target identification, drug design, prediction of toxicity, and pharmacokinetics modeling, as well as improving regulatory processes and pharmacovigilance. Though they have their benefits, there are still challenges such as data privacy, algorithmic bias, explainability, and accountability. Regulatory structures and ethical implications need to keep pace so that AI can be used safely and fairly in pharmaceuticals. This article discusses the existing applications, advantages, risks, and future possibilities of AI and ML in transforming drug development and healthcare outcomes.

---

Keywords :

Artificial Intelligence, Machine learning, pharmacokinetics modelling., post marketing surveillance, regulatory affairs

---

References :

1. Krikorian G., Torreele E. We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis. Health Hum. Rights. (2021) ;23:119–127
2. Shah H., Chavda V., Soniwala M.M. Bioinformatics Tools for Pharmaceutical Drug Product Development. Wiley; Hoboken, NJ, USA. Applications of Bioinformatics Tools in Medicinal Biology and Biotechnology; (2023), pp. 95–116.
3. Yoshida, J.G. Topliss, QSAR model for drug human oral bioavailability, J. Med. Chem., 43 (2000), pp. 2575-2585
4. Agatonovic-Kustrin and Morton. Data Mining in Drug Discovery and Design. Artificial Neural Network for Drug Design, Delivery and Disposition (2016), Pages 181-193
5. Paul, G. Sanap, S. Shenoy, D. Kalyane, K. Kalia, R.K. Tekade, Artificial intelligence in drug discovery and development, Drug Discov. Today, 26 (2021), pp. 80-93
6. Howard, Artificial intelligence: implications for the future of work, Am. J. Ind. Med., 62 (2019), pp. 917-926
7. Huanbutta et al. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. European Journal of Pharmaceutical Sciences, (2023) pp. 0928-0987
8. Reniewicz, V. Suryaprakash, J. Kowalczyk, A. Blacha, G. Kostello, H. Tan, Y. Wang, P. Reineke, D. Manissero. Artificial intelligence/machine-learning tool for post-market surveillance of in vitro diagnostic assays. N. Biotechnol., 79 (2024), pp. 82-90
9. Krishnaveni C, Arvapalli S, Sharma JV. Artificial intelligence in pharma industry-a review. International Journal of Innovative Pharmaceutical Sciences and Research. 2019 Oct 7;7(10):37-50.
10. akshi V Dashpute et al. Ijppr.Human, 2023; Vol. 28 (2): 111-131.
11. Franssen FM, Alter P, Bar N, Benedikter BJ, Iurato S,Maier D, Maxheim M, Roessler FK, Spruit MA,Vogelmeier CF, et al. Personalized medicine for patientswith COPD: Where are we? Int J Chron Obstruct PulmonDis. 2019;14:1465–1484
12. Jena GK, Patra CN,Jammula S, Rana R, Chand S.Artificial Intelligence and MachineLearning Implemented Drug DeliverySystems: A Paradigm Shift in thePharmaceutical Industry. J. Bio-XRes. 2024;7:Article 0016
13. Ryan DK, Maclean RH, Balston A, Scourfield A, Shah AD,Ross J. Artificial intelligence and machine learning forclinical pharmacology. Br J Clin Pharmacol. 2024;90(3):629–639
14. Kobayashi K, Kuromatsu N, Kobashi H, Ueda H. Platform toaccelerate utilization and R&D of AI technologies. Fujitsu SciTech J. 2020;56(1):97–102.
15. A. Alowais, et al. Badreldin. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med. Educ., 23 (2023), p. 689